Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases

Dear Colleagues,

A new program solicitation (RFA-AI-21-020) is now available:

Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)

Please see  https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-020.html for details.

Earliest submission date: June 02, 2021 following standard due date outlined in the FOA until July 07, 2023.

For timely responses to your questions, please direct your email messages to:



From the Program Solicitation:

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation.


As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.

Estimated Number of Awards:  NIAID intends to commit $1,350,000 in FY 2022 to fund up to 3 awards.

Activity Code (e.g., RO1, U01)
Funding Announcement Number
Posted Date
Expiration Date
Application Due Date
Participating Organizations
Table sorting checkbox